All In Biotech

Drug Trial Radar · NCT02308111

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis

Last checked: Nov 20, 2026Latest source record: Mar 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 334 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

334

Actual

Start

Dec 26, 2014

Primary completion

Dec 23, 2021

Study completion Dec 23, 2021

Sponsor

Lead sponsor
Intercept PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Biliary Cholangitis (PBC) is a serious, life-threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist that is derived from the primary human bile acid chenodeoxycholic acid. The key mechanisms of action of OCA, including its choleretic, anti-inflammatory, and anti-fibrotic properties, underlie its hepatoprotective effects and result in attenuation of injury and improved liver function in a cholestatic liver disease such as PBC. The study will assess the effect of OCA compared to placebo, combined with stable standard care, on clinical outcomes in PBC participants.

Conditions

  • Liver Cirrhosis, Biliary

Interventions

  • Obeticholic Acid (OCA)Drug

    Non-cirrhotic and classified as CP Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of participants). Cirrhotic and classified as CP Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study.

  • PlaceboDrug

    One tablet daily (or a lower frequency depending on CP score) for the remainder of the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the First Occurrence of Composite EndpointTime frame: Time to first occurrence from date of randomization until the time to accrue approximately 127 primary endpoint events (up to 7 years)
  2. Time to the First Occurrence of Primary Clinical Event (Expanded Endpoint)Time frame: Time to first occurrence from date of randomization until the time to accrue approximately 127 primary endpoint events (up to 7 years)

Locations

181 sites in 31 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Inland Empire Liver Foundation

    Rialto, California

  • University of California Davis, Davis Medical Center

    Sacramento, California

  • Stanford University

    Stanford, California

  • University of Colorado Denver and Hospital

    Aurora, Colorado

  • UF Hepatology Research at CTRB

    Gainesville, Florida

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida

  • Piedmont Atlanta Hospital

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Gastrointestinal Specialists of Georgia

    Marietta, Georgia

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Indianapolis Gastroenterology Research Foundation

    Indianapolis, Indiana

  • University of Louisville, Medical Dental Complex

    Louisville, Kentucky

  • Tulane University Medical Center

    New Orleans, Louisiana

  • Mercy Medical Center

    Baltimore, Maryland

  • UMass Medical School

    Worcester, Massachusetts

  • Henry Ford Health System

    Novi, Michigan

  • Minnesota Gastroenterology, P.A.

    Saint Paul, Minnesota

  • Southern Therapy and Advanced Research (STAR)

    Jackson, Mississippi

  • Kansas City Research Institute

    Kansas City, Missouri

  • Saint Louis University Gastroenterology & Hepatology

    St Louis, Missouri

  • Saint Joseph's Regional Medical Center

    Paterson, New Jersey

  • Mount Sinai Beth Israel

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Quality Medical Research, PLLC

    Nashville, Tennessee

  • The Liver Institute at Methodist Dallas Medical Center

    Dallas, Texas

  • Baylor University Medical Center

    Dallas, Texas

  • Texas Digestive Disease Consultants

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • Brooke Army Medical Center

    Fort Sam Houston, Texas

  • Baylor Scott and White Research Institute

    Fort Worth, Texas

  • Baylor College of Medicine - Advanced Liver Therapies

    Houston, Texas

  • UT Health The University of Texas Health Science Center at Houston

    Houston, Texas

  • American Research Corporation at Texas Liver Institute

    San Antonio, Texas

  • Texas Digestive Disease Consultants

    Southlake, Texas

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.